Letter by Kizawa et al Regarding Article, “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”
- 15 September 2020
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 142 (11), E154-E155
- https://doi.org/10.1161/circulationaha.120.047232
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer A Population-Based Cohort StudyCirculation, 2020
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsThe New England Journal of Medicine, 2017
- Cardiovascular Disease After Aromatase Inhibitor UseJAMA Oncology, 2016
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016